Eurosets and Estor announce a strategic partnership for the exclusive distribution of Polymyxin B hemoperfusion therapy in France, Belgium, Netherlands, Luxemburg and Austria
This strategic alliance between Eurosets and Estor will further contribute to the advancement of Polymyxin B hemoperfusion therapy, both in the area of post-cardiac surgery and in the general intensive care itself, so that Polymyxin B hemoperfusion can be available to a larger patient population in Europe.
- This strategic alliance between Eurosets and Estor will further contribute to the advancement of Polymyxin B hemoperfusion therapy, both in the area of post-cardiac surgery and in the general intensive care itself, so that Polymyxin B hemoperfusion can be available to a larger patient population in Europe.
- Polymyxin B hemoperfusion is the reference complementary therapy for neutralizing endotoxin in human blood, combining the unique properties of Polymyxin B and blood purification therapy.
- More than 250,000 patients have been treated with Polymyxin B hemoperfusion therapy worldwide and more than 400 peer-reviewed articles are available in the literature.
- “This strategic alliance between Eurosets and Estor represents a milestone that will contribute further to Polymyxin B hemoperfusion advancement in post-cardiac surgery and general intensive care for the benefit of patients in Europe,” said Dr. Mattia Corrado Bellaviti, CEO Estor.